Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

PVLA Palvella Therapeutics Inc

16,88

0,73 (4,52%)

12 Fev 2025 - Fechado

Atrasado em 15 minutos

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Palvella Therapeutics (NASDAQ:PVLA)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025

Click aqui para mais gráficos Palvella Therapeutics.

Palvella Therapeutics (NASDAQ:PVLA)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025

Click aqui para mais gráficos Palvella Therapeutics.

Notícias Palvella Therapeutics Inc

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
Segunda, 10 de Fevereiro de 2025 (2 dias atrás) • Edgar (US Regulatory)

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
Segunda, 10 de Fevereiro de 2025 (3 dias atrás) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Sexta, 7 de Fevereiro de 2025 (5 dias atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Sexta, 7 de Fevereiro de 2025 (5 dias atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Sexta, 7 de Fevereiro de 2025 (5 dias atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Sexta, 7 de Fevereiro de 2025 (5 dias atrás) • Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Sexta, 17 de Janeiro de 2025 (4 semanas atrás) • Edgar (US Regulatory)

Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
Sexta, 10 de Janeiro de 2025 (1 mês atrás) • GlobeNewswire Inc.

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Quarta, 8 de Janeiro de 2025 (1 mês atrás) • Edgar (US Regulatory)

Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
Quarta, 8 de Janeiro de 2025 (1 mês atrás) • GlobeNewswire Inc.

Form 3/A - Initial statement of beneficial ownership of securities: [Amend]
Segunda, 6 de Janeiro de 2025 (1 mês atrás) • Edgar (US Regulatory)

Form S-1 - General form for registration of securities under the Securities Act of 1933
Terça, 31 de Dezembro de 2024 (1 mês atrás) • Edgar (US Regulatory)

Mais Notícias de Palvella Therapeutics Inc

Índice Bovespa

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições